• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Guiding antimicrobial stewardship through thoughtful antimicrobial susceptibility testing and reporting strategies: an updated approach in 2023.通过深思熟虑的抗菌药物敏感性测试和报告策略指导抗菌药物管理:2023 年的更新方法。
J Clin Microbiol. 2023 Nov 21;61(11):e0007422. doi: 10.1128/jcm.00074-22. Epub 2023 Sep 28.
2
Role of the Clinical Microbiology Laboratory in Antimicrobial Stewardship.临床微生物学实验室在抗菌药物管理中的作用。
Med Clin North Am. 2018 Sep;102(5):883-898. doi: 10.1016/j.mcna.2018.05.003. Epub 2018 Jul 14.
3
Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party.治疗多重耐药革兰氏阴性菌引起的感染:英国抗菌化疗学会/医疗保健感染学会/英国感染协会联合工作组的报告。
J Antimicrob Chemother. 2018 Mar 1;73(suppl_3):iii2-iii78. doi: 10.1093/jac/dky027.
4
Introducing the new face of CLSI M100 in 2023: An explanatory review.2023 年推出的 CLSI M100 新版本:解说性评论。
Indian J Med Microbiol. 2023 Nov-Dec;46:100432. doi: 10.1016/j.ijmmb.2023.100432. Epub 2023 Aug 8.
5
Antimicrobial susceptibility testing: An updated primer for clinicians in the era of antimicrobial resistance: Insights from the Society of Infectious Diseases Pharmacists.抗菌药物敏感性试验:抗菌药物耐药时代临床医生的最新入门指南:来自传染病药师协会的见解
Pharmacotherapy. 2023 Apr;43(4):264-278. doi: 10.1002/phar.2781. Epub 2023 Mar 16.
6
Antibiotics resistance as a major public health concern: A pharmaco-epidemiological study to evaluate prevalence and antibiotics susceptibility-resistance pattern of bacterial isolates from multiple teaching hospitals.抗生素耐药性作为主要的公共卫生关注点:一项药物流行病学研究,评估来自多家教学医院的细菌分离株的流行率和抗生素敏感性-耐药性模式。
J Infect Public Health. 2023 Dec;16 Suppl 1:61-68. doi: 10.1016/j.jiph.2023.09.019. Epub 2023 Oct 23.
7
Exploring bacterial resistance in Northern Oman, a foundation for implementing evidence-based antimicrobial stewardship program.探索阿曼北部的细菌耐药性,为实施基于证据的抗菌药物管理计划奠定基础。
Int J Infect Dis. 2019 Jun;83:77-82. doi: 10.1016/j.ijid.2019.04.004. Epub 2019 Apr 5.
8
Current and Future Opportunities for Rapid Diagnostics in Antimicrobial Stewardship.当前和未来在抗菌药物管理中快速诊断的机会。
Med Clin North Am. 2018 Sep;102(5):899-911. doi: 10.1016/j.mcna.2018.05.004. Epub 2018 Jul 14.
9
Implementation of an antimicrobial stewardship program in a veterinary medical teaching institution.在兽医教学机构中实施抗菌药物管理计划。
J Am Vet Med Assoc. 2021 Jan 15;258(2):170-178. doi: 10.2460/javma.258.2.170.
10
Rapid microbiological tests for bloodstream infections due to multidrug resistant Gram-negative bacteria: therapeutic implications.快速微生物学检测多重耐药革兰氏阴性菌引起的血流感染:治疗意义。
Clin Microbiol Infect. 2020 Jun;26(6):713-722. doi: 10.1016/j.cmi.2019.09.023. Epub 2019 Oct 11.

引用本文的文献

1
Trends in Antibiotic Resistance in Uropathogens at Mbarara Regional Referral Hospital (2019-2024): A Retrospective Study.姆巴拉拉地区转诊医院尿路病原体的抗生素耐药性趋势(2019 - 2024年):一项回顾性研究
Infect Drug Resist. 2025 Aug 4;18:3875-3890. doi: 10.2147/IDR.S523848. eCollection 2025.
2
Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions.《临床和实验室标准协会抗菌药物敏感性试验性能标准的变化概述:M100第32版和第33版》
J Clin Microbiol. 2025 Sep 10;63(9):e0162323. doi: 10.1128/jcm.01623-23. Epub 2025 Aug 7.
3
Prevalence of Methicillin-Resistant (MRSA) in Egyptian Water Buffaloes and Risk Factors for Subclinical Mastitis.埃及水牛中耐甲氧西林金黄色葡萄球菌(MRSA)的流行情况及亚临床乳腺炎的危险因素
Transbound Emerg Dis. 2025 Jul 1;2025:8862271. doi: 10.1155/tbed/8862271. eCollection 2025.
4
Daidzein-Decorated Gold Nanoparticles as a Novel Antimicrobial Strategy Against Carbapenem-Resistant Enterobacteriaceae.大豆苷元修饰的金纳米颗粒作为一种抗碳青霉烯类耐药肠杆菌科细菌的新型抗菌策略。
Int J Nanomedicine. 2025 Jun 19;20:7811-7827. doi: 10.2147/IJN.S515798. eCollection 2025.
5
Selective reporting of antibiotic susceptibility testing results: a retrospective evaluation of a nudging strategy to improve antibiotic prescribing for ampC-producing infections in hospitalized adults.抗生素敏感性测试结果的选择性报告:对一项助推策略的回顾性评估,该策略旨在改善住院成人产AmpC感染的抗生素处方情况
Ther Adv Infect Dis. 2025 Jun 20;12:20499361251338017. doi: 10.1177/20499361251338017. eCollection 2025 Jan-Dec.
6
Point-Counterpoint: Cascade reporting-useful tool to support antimicrobial stewardship, or dangerously misleading.针锋相对:级联报告——支持抗菌药物管理的有用工具,还是具有危险误导性?
J Clin Microbiol. 2025 Jul 9;63(7):e0170824. doi: 10.1128/jcm.01708-24. Epub 2025 Jun 17.
7
Antimicrobial resistance: Current challenges and future directions.抗菌药物耐药性:当前挑战与未来方向。
Med J Armed Forces India. 2025 May-Jun;81(3):247-258. doi: 10.1016/j.mjafi.2024.07.006. Epub 2024 Sep 19.
8
Significant changes in gut microbiota and SCFAs among patients with newly diagnosed acute myeloid leukemia.新诊断急性髓系白血病患者肠道微生物群和短链脂肪酸的显著变化。
Front Microbiol. 2025 Apr 1;16:1559033. doi: 10.3389/fmicb.2025.1559033. eCollection 2025.
9
New Option for Antibiotic Susceptibility Testing in Clinical Practice: Performance Evaluation of AutoMic-i600 Automatic System Based on Broth Microdilution Method.临床实践中抗生素敏感性检测的新选择:基于肉汤微量稀释法的AutoMic-i600自动系统性能评估
Infect Drug Resist. 2025 Jan 28;18:543-556. doi: 10.2147/IDR.S499486. eCollection 2025.
10
Synthesis of new triazole derivatives and their potential applications for removal of heavy metals from aqueous solution and antibacterial activities.新型三唑衍生物的合成及其从水溶液中去除重金属的潜在应用和抗菌活性。
Front Chem. 2024 Oct 23;12:1473097. doi: 10.3389/fchem.2024.1473097. eCollection 2024.

本文引用的文献

1
Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections.美国传染病学会2023年抗微生物药物耐药革兰氏阴性菌感染治疗指南
Clin Infect Dis. 2023 Jul 18. doi: 10.1093/cid/ciad428.
2
Potential of Inaccurate Cefiderocol Susceptibility Results: a CLSI AST Subcommittee Advisory.头孢地尔药敏结果不准确的可能性:CLSI抗菌药物敏感性试验分委员会的建议
J Clin Microbiol. 2023 Apr 20;61(4):e0160022. doi: 10.1128/jcm.01600-22. Epub 2023 Mar 22.
3
Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs.2016 - 19年新抗生素监管批准时的证据及成本:对美国食品药品监督管理局批准药物的队列研究
BMJ Med. 2022 Dec 12;1(1):e000227. doi: 10.1136/bmjmed-2022-000227. eCollection 2022.
4
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections.美国传染病学会关于治疗产 AmpC β-内酰胺酶肠杆菌科、耐碳青霉烯类鲍曼不动杆菌和嗜麦芽窄食单胞菌感染的指南。
Clin Infect Dis. 2022 Jul 6;74(12):2089-2114. doi: 10.1093/cid/ciab1013.
5
Treatment Considerations for CNS Infections Caused by Vancomycin-Resistant : A Focused Review of Linezolid and Daptomycin.治疗耐万古霉素肠球菌引起的中枢神经系统感染的考虑因素:利奈唑胺和达托霉素的重点综述。
Ann Pharmacother. 2020 Dec;54(12):1243-1251. doi: 10.1177/1060028020932513. Epub 2020 Jun 8.
6
Nudging In MicroBiology Laboratory Evaluation (NIMBLE): A scoping review.推动微生物学实验室评估(NIMBLE):范围综述。
Infect Control Hosp Epidemiol. 2019 Dec;40(12):1400-1406. doi: 10.1017/ice.2019.293. Epub 2019 Nov 4.
7
Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute.临床和实验室标准研究所制定的粪肠球菌达托霉素药敏折点的发展和其他肠球菌种折点的修订。
Clin Infect Dis. 2020 Mar 3;70(6):1240-1246. doi: 10.1093/cid/ciz845.
8
The Infectious Diseases Society of America's 10 × '20 Initiative (10 New Systemic Antibacterial Agents US Food and Drug Administration Approved by 2020): Is 20 × '20 a Possibility?美国传染病学会的 10×20 倡议(10 种新的全身性抗菌药物于 2020 年获得美国食品和药物管理局批准):20×20 是否有可能?
Clin Infect Dis. 2019 Jun 18;69(1):1-11. doi: 10.1093/cid/ciz089.
9
APPROVED: New Antimicrobial Stewardship Standard.批准:新的抗菌药物管理标准。
Jt Comm Perspect. 2016 Jul;36(7):1, 3-4, 8.
10
Executive Summary: Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.执行摘要:实施抗生素管理计划:美国传染病学会和美国医疗保健流行病学学会的指南。
Clin Infect Dis. 2016 May 15;62(10):1197-1202. doi: 10.1093/cid/ciw217.

通过深思熟虑的抗菌药物敏感性测试和报告策略指导抗菌药物管理:2023 年的更新方法。

Guiding antimicrobial stewardship through thoughtful antimicrobial susceptibility testing and reporting strategies: an updated approach in 2023.

机构信息

Department of Pathology, University of Michigan Medical School , Ann Arbor, Michigan, USA.

Department of Medicine, Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School , New Brunswick, New Jersey, USA.

出版信息

J Clin Microbiol. 2023 Nov 21;61(11):e0007422. doi: 10.1128/jcm.00074-22. Epub 2023 Sep 28.

DOI:10.1128/jcm.00074-22
PMID:37768094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10662363/
Abstract

Antimicrobial susceptibility test and report guidelines are an important tool for antimicrobial stewardship programs. Since 1972, Tables 1 within the Clinical and Laboratory Standards Institute (CLSI) M100 document have provided a general framework upon which clinical microbiologists and antimicrobial stewardship teams can build algorithms for susceptibility testing and reporting that meet the specific needs of their institution. Many changes were made to Tables 1 in M100-Ed33 to modernize the content to reflect the landscape of current clinical practice, including the growing armamentarium of antimicrobial agents, the emergence of new mechanisms of antimicrobial resistance, the increasing prevalence of infections caused by multidrug-resistant organisms, and updated consensus recommendations for first-choice and alternative agents for treatment. With these items in mind, the CLSI Table 1 working group revised Tables 1 with the ultimate goal of supporting institutions in the creation of individualized test and report strategies that support local antimicrobial stewardship program initiatives. These strategies are built on the concepts of selective and cascade reporting. This minireview introduces the concept of CLSI M100-Ed33 Tables 1, describes the changes to Tables 1 introduced in 2023, and provides clinical vignettes that demonstrate how Tables 1 can be used in various scenarios to devise antimicrobial susceptibility test and report strategies.

摘要

抗菌药物敏感性试验和报告指南是抗菌药物管理计划的重要工具。自 1972 年以来,临床和实验室标准协会(CLSI)M100 文件中的表 1 为临床微生物学家和抗菌药物管理团队提供了一个通用框架,可以在此基础上构建满足其机构具体需求的药敏试验和报告算法。为了使内容现代化,以反映当前临床实践的情况,包括抗菌药物武器库的不断扩大、新的抗菌药物耐药机制的出现、多药耐药生物体引起的感染的流行率不断增加,以及更新的首选和替代治疗药物的共识建议,M100-Ed33 版对表 1 进行了许多修改。考虑到这些因素,CLSI 表 1 工作组对表 1 进行了修订,最终目标是支持各机构制定个体化的试验和报告策略,以支持当地的抗菌药物管理计划举措。这些策略建立在选择性和级联报告的概念之上。本文简要介绍了 CLSI M100-Ed33 表 1 的概念,描述了 2023 年引入的表 1 的变化,并提供了临床病例,展示了如何在各种情况下使用表 1 来设计抗菌药物敏感性试验和报告策略。